BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28453027)

  • 1. [Prevalence of potential drug-drug interactions involving antiretroviral drugs in Buenos Aires, Argentina].
    Córdova E; Porteiro N; Loiza E; Mingrone H
    Rev Chilena Infectol; 2016 Oct; 33(Suppl 1):54-59. PubMed ID: 28453027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential drug-drug interactions in HIV-perinatally infected adolescents on antiretroviral therapy in Buenos Aires, Argentina.
    Cordova E; Cecchini D; Rodriguez C
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19764. PubMed ID: 25397508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].
    Cervero M; Torres R; Jusdado JJ; Pastor S; Agud JL
    Med Clin (Barc); 2016 Apr; 146(8):339-45. PubMed ID: 26971988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.
    Tseng A; Szadkowski L; Walmsley S; Salit I; Raboud J
    Ann Pharmacother; 2013 Nov; 47(11):1429-39. PubMed ID: 24285760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of comedications and potential drug-drug interactions in people living with HIV in China.
    Chen R; Chen J; Tang Q; Meng Z; Luo L; Zhang W; Deng A; Zhang L; Wang J; Qi T; Zhang R; Shen Y; Liu L; Steinhart C; Lu H
    J Infect Chemother; 2020 Jul; 26(7):722-728. PubMed ID: 32354599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of antiretroviral drug therapy in Jamaican children with HIV/AIDS.
    Pryce C; Pierre RB; Steel-Duncan J; Evans-Gilbert T; Palmer P; Moore J; Rodriguez B; Christie CD
    West Indian Med J; 2008 Jun; 57(3):238-45. PubMed ID: 19583122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older.
    Ranzani A; Oreni L; Agrò M; van den Bogaart L; Milazzo L; Giacomelli A; Cattaneo D; Gervasoni C; Ridolfo AL
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):193-201. PubMed ID: 29767640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
    Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
    J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Impact of a Pharmacist-Led Antiretroviral Stewardship Program on Reducing Drug Interactions in HIV-Infected Patients.
    Billedo JA; Berkowitz LB; Cha A
    J Int Assoc Provid AIDS Care; 2016; 15(1):84-8. PubMed ID: 26289342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina.
    Dilernia DA; Lourtau L; Gomez AM; Ebenrstejin J; Toibaro JJ; Bautista CT; Marone R; Carobene M; Pampuro S; Gomez-Carrillo M; Losso MH; Salomón H
    AIDS; 2007 Jun; 21(10):1355-60. PubMed ID: 17545713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
    So-Ngern A; Montakantikul P; Manosuthi W
    Southeast Asian J Trop Med Public Health; 2014 Sep; 45(5):1023-31. PubMed ID: 25417503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.
    Iniesta-Navalón C; Franco-Miguel JJ; Gascón-Cánovas JJ; Rentero-Redondo L
    HIV Med; 2015 May; 16(5):273-9. PubMed ID: 25523089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda.
    Seden K; Merry C; Hewson R; Siccardi M; Lamorde M; Byakika-Kibwika P; Laker E; Parkes-Ratanshi R; Back DJ; Khoo SH
    J Antimicrob Chemother; 2015 Dec; 70(12):3317-22. PubMed ID: 26286575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
    Halloran MO; Boyle C; Kehoe B; Bagkeris E; Mallon P; Post FA; Vera J; Williams I; Anderson J; Winston A; Sachikonye M; Sabin C; Boffito M
    Antivir Ther; 2019; 24(3):193-201. PubMed ID: 30700636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
    Miller CD; El-Kholi R; Faragon JJ; Lodise TP
    Pharmacotherapy; 2007 Oct; 27(10):1379-86. PubMed ID: 17896893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.